This was obviously always the risk with a biotech, and all holders are aware of it. The upside was so tempting. But the kick in the guts is still that. In terms of cash burn, cutting back on this means a much longer story here (cutting staff, raising capital, renewing strategy etc). Can anyone recommend such as long book?
beginning of end ...., page-8
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
